Physician profile
Pascal Saremsky
NPI 1861767931
$5,725.44
in general payments reported to CMS, 2019-2025
37 companies · $1,066 in 2025
The $1,066 reported for 2025 was more than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $435 · 2020: $442 · 2021: $472 · 2022: $1,060 · 2023: $959 · 2024: $1,292 · 2025: $1,066.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,317.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,316.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $1,159.54 | 2019-2024 | Jornay Pm |
| Corium, LLC | $890.09 | 2022-2025 | Azstarys |
| Neurelis, INC. | $621.25 | 2020-2025 | Valtoco |
| Neos Therapeutics, Lp | $538.50 | 2020-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Tris Pharma INC | $362.12 | 2019-2025 | Dyanavel Xr, Onyda Xr |
| Supernus Pharmaceuticals, INC. | $354.07 | 2021-2024 | Qelbree, Qelbree |
| Collegium Pharmaceutical, INC. | $328.27 | 2025 | Jornay Pm |
| Ucb, INC. | $291.15 | 2021-2025 | Briviact, Fintepla, Rystiggo |
| Abbvie INC. | $237.54 | 2022-2025 | Qulipta |
| Sunovion Pharmaceuticals INC. | $155.77 | 2019 | |
| Biomarin Pharmaceutical INC. | $73.73 | 2019-2022 | |
| Eisai INC. | $62.44 | 2024 | |
| Avion Pharmaceuticals | $56.56 | 2023 | Methylphenidate Hydrochloride |
| Biohaven Pharmaceutical Holding Company Ltd. | $55.63 | 2022 | |
| Vertical Pharmaceuticals, LLC | $54.60 | 2019-2024 | Relexxii |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $44.97 | 2023 | Percept Pc Brainsense |
| Lilly USA, LLC | $40.42 | 2022 | |
| Bioventus LLC | $33.09 | 2019-2021 | |
| Harmony Biosciences LLC | $29.28 | 2024 | |
| Glaxosmithkline, LLC. | $26.13 | 2019 | |
| Allergan, INC. | $25.87 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $25.54 | 2023 | Dysport |
| Abbott Laboratories | $23.87 | 2022 | |
| Adlon Therapeutics L.P. | $22.29 | 2020 | |
| Pfizer INC. | $20.18 | 2024 | |
| Avanir Pharmaceuticals, INC. | $19.39 | 2019 | |
| Almatica Pharma LLC | $19.29 | 2023 | Gralise |
| Grifols USA, LLC | $18.88 | 2022 | |
| Merck Sharp & Dohme LLC | $18.64 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $16.63 | 2022 | |
| Aquestive Therapeutics, INC. | $15.89 | 2022 | |
| Melinta Therapeutics, LLC | $15.55 | 2019 | |
| Upsher-Smith Laboratories LLC | $15.36 | 2020 | |
| Greenwich Biosciences, INC. | $14.80 | 2021 | |
| Biogen, INC. | $14.03 | 2019 | |
| Currax Pharmaceuticals LLC | $12.63 | 2020 | |
| Medtronic USA, INC. | $11.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pascal Saremsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.